Hunan Jiudian Pharmaceutical (300705.SZ) has obtained a drug registration certificate.
Jiudian Pharmaceutical (300705.SZ) announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The drug is named: Fumaric Acid Ebastine Sustained-Release Capsules. Fumaric Acid Ebastine Sustained-Release Capsules are used to treat allergic rhinitis and urticaria.
Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for a drug named: Fumaric acid emestine sustained-release capsules. Fumaric acid emestine sustained-release capsules are used for the treatment of allergic rhinitis and urticaria.
Related Articles
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Shenzhen Stock Exchange: Nations Technologies Inc. (02701) will be included in the list of eligible stocks for the Shenzhen-Hong Kong Stock Connect.
CITIC SEC: Optimistic about storage investment opportunities in the AI era with a combination of cycles, growth, and domestic resonance.
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Shenzhen Stock Exchange: Nations Technologies Inc. (02701) will be included in the list of eligible stocks for the Shenzhen-Hong Kong Stock Connect.
CITIC SEC: Optimistic about storage investment opportunities in the AI era with a combination of cycles, growth, and domestic resonance.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
